What patient factors do you feel are most important when considering reduced dosing regimens of IL17a inhibitors such as secukinumab and ixekizumab for psoriasis?

If the psoriasis is completely clear, the patient may wonder if they need to continue treatment. If they want to spread out the doses to see how little they need, I usually have no objection.